Andrew D Mihalek1, Ivan O Rosas2, Robert F Padera3, Anne L Fuhlbrigge4, Gary M Hunninghake5, Dawn L DeMeo6, Phillip C Camp7, Hilary J Goldberg8. 1. Division of Pulmonary and Critical Care Medicine, Boston, MA. 2. Department of Medicine; Lung Transplant Program, Division of Pulmonary and Critical Care Medicine, Boston, MA; Lovelace Respiratory Research Institute, Albuquerque, NM; Harvard Medical School, Boston, MA. 3. Department of Medicine; Department of Pathology, Brigham and Women's Hospital, Boston, MA; Harvard Medical School, Boston, MA. 4. Department of Medicine; Lung Transplant Program, Division of Pulmonary and Critical Care Medicine, Boston, MA; Harvard Medical School, Boston, MA. 5. Division of Pulmonary and Critical Care Medicine, Boston, MA; Harvard Medical School, Boston, MA. 6. Department of Medicine; Lung Transplant Program, Division of Pulmonary and Critical Care Medicine, Boston, MA; Channing Laboratory, Brigham and Women's Hospital, Boston, MA; Harvard Medical School, Boston, MA. 7. Lung Transplant Program, Division of Thoracic Surgery, Brigham and Women's Hospital, Boston, MA; Harvard Medical School, Boston, MA. 8. Department of Medicine; Lung Transplant Program, Division of Pulmonary and Critical Care Medicine, Boston, MA; Harvard Medical School, Boston, MA. Electronic address: hjgoldberg@partners.org.
Abstract
BACKGROUND: The presence of interstitial pneumonitis (IP) on surveillance lung biopsy specimens in lung transplant recipients is poorly described, and its impact on posttransplant outcomes is not established. The following study assessed the association of posttransplant IP with the development of bronchiolitis obliterans syndrome (BOS). METHODS: We examined all recipients of primary cadaveric lung transplants at our institution between January 1, 2000, and December 31, 2007 (N = 145). Patients had bronchoscopies with BAL, and transbronchial biopsies performed for surveillance during posttransplant months 1, 3, 6, and 12 as well as when clinically indicated. Patients were given a diagnosis of IP if, in the absence of active infection and organizing pneumonia, they showed evidence of interstitial inflammation and fibrosis on two or more biopsy specimens. RESULTS: IP was a significant predictor of BOS (OR, 7.84; 95% CI, 2.84-21.67; P < .0001) and was significantly associated with time to development of BOS (hazard ratio, 3.8; 95% CI, 1.93-7.39; P = .0001) within the first 6 years posttransplant. The presence of IP did not correlate with a significantly higher risk of mortality or time to death. There was no association between the presence of IP and the development of or time to acute rejection. CONCLUSIONS: The presence of IP on lung transplant biopsy specimens suggests an increased risk for BOS, which is independent of the presence of acute cellular rejection.
BACKGROUND: The presence of interstitial pneumonitis (IP) on surveillance lung biopsy specimens in lung transplant recipients is poorly described, and its impact on posttransplant outcomes is not established. The following study assessed the association of posttransplant IP with the development of bronchiolitis obliterans syndrome (BOS). METHODS: We examined all recipients of primary cadaveric lung transplants at our institution between January 1, 2000, and December 31, 2007 (N = 145). Patients had bronchoscopies with BAL, and transbronchial biopsies performed for surveillance during posttransplant months 1, 3, 6, and 12 as well as when clinically indicated. Patients were given a diagnosis of IP if, in the absence of active infection and organizing pneumonia, they showed evidence of interstitial inflammation and fibrosis on two or more biopsy specimens. RESULTS: IP was a significant predictor of BOS (OR, 7.84; 95% CI, 2.84-21.67; P &lt; .0001) and was significantly associated with time to development of BOS (hazard ratio, 3.8; 95% CI, 1.93-7.39; P = .0001) within the first 6 years posttransplant. The presence of IP did not correlate with a significantly higher risk of mortality or time to death. There was no association between the presence of IP and the development of or time to acute rejection. CONCLUSIONS: The presence of IP on lung transplant biopsy specimens suggests an increased risk for BOS, which is independent of the presence of acute cellular rejection.
Authors: Marc Estenne; Janet R Maurer; Annette Boehler; James J Egan; Adaani Frost; Marshall Hertz; George B Mallory; Gregory I Snell; Samuel Yousem Journal: J Heart Lung Transplant Date: 2002-03 Impact factor: 10.247
Authors: Jason D Christie; Leah B Edwards; Anna Y Kucheryavaya; Christian Benden; Fabienne Dobbels; Richard Kirk; Axel O Rahmel; Josef Stehlik; Marshall I Hertz Journal: J Heart Lung Transplant Date: 2011-10 Impact factor: 10.247
Authors: M Rinaldi; L Martinelli; G Volpato; C Pederzolli; M Silvestri; N Pederzolli; E Arbustini; M Vigano Journal: Transplant Proc Date: 1995-06 Impact factor: 1.066
Authors: C M Burke; J Theodore; K D Dawkins; S A Yousem; N Blank; M E Billingham; A Van Kessel; S W Jamieson; P E Oyer; J C Baldwin Journal: Chest Date: 1984-12 Impact factor: 9.410
Authors: Edward Cantu; James Z Appel; Matthew G Hartwig; Hiwot Woreta; Cindy Green; Robert Messier; Scott M Palmer; R Duane Davis Journal: Ann Thorac Surg Date: 2004-10 Impact factor: 4.330
Authors: K Bando; I L Paradis; S Similo; H Konishi; K Komatsu; T G Zullo; S A Yousem; J M Close; A Zeevi; R J Duquesnoy Journal: J Thorac Cardiovasc Surg Date: 1995-07 Impact factor: 5.209
Authors: Marc Hartert; Omer Senbaklavacin; Bernhard Gohrbandt; Berthold M Fischer; Roland Buhl; Christian-Friedrich Vahld Journal: Dtsch Arztebl Int Date: 2014-02-14 Impact factor: 5.594
Authors: Lee Gazourian; Samuel Ash; Emily E K Meserve; Alejandro Diaz; Raul San Jose Estepar; Souheil Y El-Chemaly; Ivan O Rosas; Miguel Divo; Anne L Fuhlbrigge; Phillip C Camp; Vincent T Ho; Ami S Bhatt; Hilary J Goldberg; Lynette M Sholl; George R Washko Journal: Clin Transplant Date: 2017-04-12 Impact factor: 2.863